NOVOCURE LIMITED

(NVCR)
  Report
Delayed Nasdaq  -  04:00 2022-08-05 pm EDT
75.62 USD   +0.99%
08/04INSIDER SELL : Novocure
MT
07/29Truist Securities Drops NovoCure's Price Target to $105 From $118, Keeps Buy Rating
MT
07/29Piper Sandler Adjusts NovoCure's Price Target to $90 From $100, Reiterates Overweight Rating
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news
Most relevant news about NOVOCURE LIMITED
08/04INSIDER SELL : Novocure
MT
07/29Truist Securities Drops NovoCure's Price Target to $105 From $118, Keeps Buy Rating
MT
07/29Piper Sandler Adjusts NovoCure's Price Target to $90 From $100, Reiterates Overweight R..
MT
07/28NovoCure Q2 Loss Widens, Net Revenue Rises
MT
07/28TRANSCRIPT : NovoCure Limited, Q2 2022 Earnings Call, Jul 28, 2022
CI
07/28NOVOCURE : Q2 Earnings Snapshot
AQ
07/28NOVOCURE : Quarterly net revenues of $140.9 million, a 6% increase year-over-year - Form 8..
PU
07/28Novocure Reports Second Quarter 2022 Financial Results
BU
07/28NovoCure Limited Reports Earnings Results for the Second Quarter and Six Months Ended J..
CI
07/28Earnings Flash (NVCR) NOVOCURE Reports Q2 Loss $-0.23
MT
07/28Earnings Flash (NVCR) NOVOCURE Reports Q2 Revenue $140.9M
MT
07/27Novocure Announces Recipients of 4th Annual AACR-Novocure Grants for Tumor Treating Fie..
BU
07/11Wedbush Sees Continued Modest Growth in NovoCure's Optune Franchise
MT
07/05Evercore ISI Downgrades NovoCure to Underperform From In-Line
MT
07/01Novocure to Report Second Quarter 2022 Financial Results
BU
06/24NOVOCURE LIMITED(NASDAQGS : NVCR) added to Russell 2500 Index
CI
06/24NOVOCURE LIMITED(NASDAQGS : NVCR) added to Russell 2500 Growth Index
CI
06/21NovoCure Enrolls First Patient in Study of Tumor Treating Fields, Keytruda Combination ..
MT
06/21Novocure Enrolls First Patient in KEYNOTE-B36, a Pilot Study of Tumor Treating Fields T..
BU
06/21Novocure Enrolls First Patient in KEYNOTE-B36, a Pilot Study of Tumor Treating Fields T..
CI
06/06HC Wainwright Initiates NovoCure at Buy, Sets Price Target at $115
MT
06/03Novocure Falls 5%, Zai Lab Rises 8%; Companies Report Study Results
DJ
06/03Zai Lab, Novocure's Phase 2 Study of Gastric Cancer Combination Therapy Meets Primary E..
MT
06/03NOVOCURE : Press Release of NovoCure Limited, dated June 3, 2022 - Form 8-K
PU
06/03Novocure and Zai Lab Announce EF-31 Phase 2 Pilot Study Evaluating Tumor Treating Field..
BU
06/03Novocure and Zai Lab Announce EF-31 Phase 2 Pilot Study Evaluating Tumor Treating Field..
CI
05/26SECTOR UPDATE : Health Care Stocks Propelled Higher Near Thursday Close
MT
05/26SECTOR UPDATE : Health Care Stocks Edging Higher on Thursday
MT
05/26NOVOCURE : Announces Clinical Collaboration with MSD on a Registrational-Intent Study to E..
PU
05/26NovoCure Teams Up With Merck to Study Tumor Treating Fields Combined With Keytruda to T..
MT
05/26Novocure Announces Clinical Collaboration with MSD on a Registrational-Intent Study to ..
BU
05/26NovoCure Limited Announces Clinical Collaboration with MSD on a Registrational-Intent S..
CI
05/16NovoCure's Shares Rise After HC Wainwright Initiates Coverage at Buy
MT
05/16HC Wainwright Initiates NovoCure at Buy With $115 Price Target
MT
05/13Piper Sandler Adjusts NovoCure's Price Target to $100 From $125, Reiterates Overweight ..
MT
04/28NovoCure's Q1 Net Loss Flat, Revenue Rises
MT
04/28TRANSCRIPT : NovoCure Limited, Q1 2022 Earnings Call, Apr 28, 2022
CI
04/28NOVOCURE : Q1 Earnings Snapshot
AQ
04/28NOVOCURE : Quarterly net revenues of $137.5 million with 80% gross margin - Form 8-K
PU
04/28Earnings Flash (NVCR) NOVOCURE Reports Q1 Loss $-0.04, vs. Street Est of $-0.19
MT
04/28Earnings Flash (NVCR) NOVOCURE Posts Q1 Revenue $137.5M, vs. Street Est of $134.3M
MT
04/28Novocure Reports First Quarter 2022 Financial Results
BU
04/28NovoCure Limited Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
04/19Novocure Hosts Ceremonial Groundbreaking with New Hampshire Governor Chris Sununu
BU
04/13Novocure Limited Announces Resignation of Sherilyn McCoy from the Board of Directors
CI
04/08Novocure Announces 19 Presentations at American Association for Cancer Research (AACR) ..
BU
04/04Evercore ISI Adjusts Price Target for NovoCure to $82 From $62, Maintains In-Line Ratin..
MT
04/01Novocure to Report First Quarter 2022 Financial Results
BU
03/24Updated 2-THE-TOP Data Suggest Improvements in Progression-Free Survival, Overall Survi..
BU
03/24NovoCure Limited Announces Updated 2-THE-TOP Data Suggest Improvements in Progression-F..
CI
03/23Novocure Announces Favorable Recommendation to Continue the Phase 3 Pivotal INNOVATE-3 ..
BU
03/23NovoCure's Phase 3 Study of Tumor Treating Fields Given Independent Recommendation to C..
MT
03/23NOVOCURE : Announces Favorable Recommendation to Continue the Phase 3 Pivotal INNOVATE-3 S..
PU
03/23Novocure Announces Favorable Recommendation to Continue the Phase 3 Pivotal INNOVATE-3 ..
CI
03/09INSIDER SELL : NovoCure
MT
03/09INSIDER SELL : NovoCure
MT
03/09INSIDER SELL : Novocure
MT
02/28Novocure Founder Yoram Palti Wins 2022 Israel Prize in Entrepreneurship and Technologic..
BU
02/24Novocure's General Counsel Resigns After 10 Years of Service
BU
02/24Novocure Announces Resignation of Todd Longsworth as General Counsel
CI
02/24TRANSCRIPT : NovoCure Limited, Q4 2021 Earnings Call, Feb 24, 2022
CI
02/24NovoCure Swings to Loss, Revenue Declines in Q4; Shares Fall in Premarket
MT
02/24NOVOCURE : Q4 Earnings Snapshot
AQ
02/24NOVOCURE : Invested record $201 million in 2021 in research and development initiatives in..
PU
02/24New Data Finds Tumor Treating Fields Initiates Downstream Anti-Tumor Response
BU
02/24Novocure Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Compa..
BU
02/24Novocure Announces New Data Finds Tumor Treating Fields Initiates Downstream Anti-Tumor..
CI
02/24Earnings Flash (NVCR) NOVOCURE Posts Q4 Revenue $133.2M
MT
02/24NovoCure Limited Reports Earnings Results for the Fourth Quarter Ended December 31, 202..
CI
02/24NovoCure Limited Reports Earnings Results for the Full Year Ended December 31, 2021
CI
02/08NovoCure Shares Rise After Loop Capital Initiates Coverage With Buy Rating, $200 Price ..
MT
02/08Loop Capital Starts NovoCure at Buy With $200 Price Target
MT
02/02NovoCure Shares Higher After Oppenheimer Upgrade to Outperform
MT
02/02Oppenheimer Upgrades NovoCure to Outperform From Perform; Price Target is $98
MT
01/20Health Care Stocks Higher Ahead of Thursday's Close
MT
1  2  3  4  5  6  7  8  9Next
Upcoming event on NOVOCURE LIMITED